Low-dose and long-term azithromycin significantly decreases Staphylococcus aureus in the microbiome of refractory CRS patients.
Axel Eluid RenteriaAnastasios ManiakasLeandra Endam MfunaMarc-Henri AsmarEmmanuel GonzalezMartin DesrosiersPublished in: International forum of allergy & rhinology (2020)
A 4-month course of 250 mg of azithromycin 3 times weekly in patients with refractory CRS significantly decreases S. aureus abundance in the sinonasal microbiome. Considering the pathogenic role of S. aureus in the refractory CRS population, azithromycin may constitute an additional therapeutic option to help control this disease.